Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Share Price Cross Below Two Hundred Day Moving Average – Here’s What Happened

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $30.61 and traded as low as $27.78. Lakefront Biotherapeutics American Depositary Shares shares last traded at $27.84, with a volume of 167,206 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on LKFT shares. Morgan Stanley began coverage on Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, July 10th. They issued an “equal weight” rating and a $30.00 price objective on the stock. Wall Street Zen downgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, May 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $34.33.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

The stock has a fifty day simple moving average of $28.75 and a two-hundred day simple moving average of $30.61. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -19.74 and a beta of 0.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.52. The business had revenue of $8.75 million during the quarter, compared to analyst estimates of $11.26 million. Research analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -10.83 earnings per share for the current year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Institutional investors have recently added to or reduced their stakes in the business. Madison Avenue Partners LP grew its position in shares of Lakefront Biotherapeutics American Depositary Shares by 0.8% during the 4th quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock worth $72,371,000 after buying an additional 17,394 shares during the period. Ameriprise Financial Inc. boosted its stake in Lakefront Biotherapeutics American Depositary Shares by 2,490.1% during the third quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock worth $49,083,000 after acquiring an additional 1,362,229 shares in the last quarter. UBS Group AG boosted its stake in Lakefront Biotherapeutics American Depositary Shares by 128.4% during the fourth quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after acquiring an additional 196,445 shares in the last quarter. Millennium Management LLC boosted its stake in Lakefront Biotherapeutics American Depositary Shares by 121.9% during the fourth quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock worth $11,097,000 after acquiring an additional 186,452 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in Lakefront Biotherapeutics American Depositary Shares by 2,245.7% in the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock worth $2,783,000 after purchasing an additional 115,946 shares during the period. 32.46% of the stock is owned by institutional investors and hedge funds.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.